BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 11698569)

  • 1. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men.
    Yu MW; Yang YC; Yang SY; Cheng SW; Liaw YF; Lin SM; Chen CJ
    J Natl Cancer Inst; 2001 Nov; 93(21):1644-51. PubMed ID: 11698569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma.
    Yu MW; Cheng SW; Lin MW; Yang SY; Liaw YF; Chang HC; Hsiao TJ; Lin SM; Lee SD; Chen PJ; Liu CJ; Chen CJ
    J Natl Cancer Inst; 2000 Dec; 92(24):2023-8. PubMed ID: 11121465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
    Allen NE; Forrest MS; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
    Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
    Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
    Rossi L; Leveri M; Gritti C; De Silvestri A; Zavaglia C; Sonzogni L; Silvestri L; Civardi E; Mondelli MU; Silini EM
    J Hepatol; 2003 Oct; 39(4):564-70. PubMed ID: 12971967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
    Lunn RM; Bell DA; Mohler JL; Taylor JA
    Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women.
    Yu MW; Yang YC; Yang SY; Chang HC; Liaw YF; Lin SM; Liu CJ; Lee SD; Lin CL; Chen PJ; Lin SC; Chen CJ
    Hepatology; 2002 Jul; 36(1):156-63. PubMed ID: 12085360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
    Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
    Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic impact on prostate anatomical variability during ageing: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms.
    Larré S; Hamadeh H; Azzouzi AR; Vallancien G; Cochand-Priollet B; Cancel-Tassin G; Cussenot O
    BJU Int; 2007 Sep; 100(3):679-84. PubMed ID: 17669147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypospadias risk and polymorphism in SRD5A2 and CYP17 genes: case-control study among Indian children.
    Samtani R; Bajpai M; Vashisht K; Ghosh PK; Saraswathy KN
    J Urol; 2011 Jun; 185(6):2334-9. PubMed ID: 21511288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic determinants of anatomical variants of the prostate].
    Hamadeh H; Larré S; Azzouzi AR; Cancel-Tassin G; Vallancien G; Cochand-Priollet B; Cussenot O
    Prog Urol; 2008 Apr; 18(4):214-22. PubMed ID: 18501301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
    Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
    Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
    Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
    Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
    Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of puberty onset on spontaneous hepatitis B virus e antigen seroconversion in men.
    Wu JF; Tsai WY; Hsu HY; Ni YH; Chen HL; Tsuei DJ; Chang MH
    Gastroenterology; 2010 Mar; 138(3):942-8.e1. PubMed ID: 19962986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.
    Yu MW; Yeh SH; Chen PJ; Liaw YF; Lin CL; Liu CJ; Shih WL; Kao JH; Chen DS; Chen CJ
    J Natl Cancer Inst; 2005 Feb; 97(4):265-72. PubMed ID: 15713961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis.
    Yeh SH; Chang CF; Shau WY; Chen YW; Hsu HC; Lee PH; Chen DS; Chen PJ
    Cancer Res; 2002 Aug; 62(15):4346-51. PubMed ID: 12154039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
    Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O
    Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIN1 genetic polymorphisms and the susceptibility of HBV-related hepatocellular carcinoma in a Guangxi population.
    Huang L; Mo Z; Lao X; Zhang X; Liu Y; Sui J; Qin X; Li S
    Tumour Biol; 2016 May; 37(5):6599-606. PubMed ID: 26643892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between hormonal genetic polymorphisms and early-onset prostate cancer.
    Forrest MS; Edwards SM; Houlston R; Kote-Jarai Z; Key T; Allen N; Knowles MA; Turner F; Ardern-Jones A; Murkin A; Williams S; Oram R; Bishop DT; Eeles RA;
    Prostate Cancer Prostatic Dis; 2005; 8(1):95-102. PubMed ID: 15711606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.